动脉内脏介质厚度和多发性硬化症中的动脉样硬化风险:一个横截面研究
Elyar Alizadeh Najmi1,2, Zahra Mirzaasgari1,2,3,4, Mohammad Reza Motamed1,2
1Firouzgar Clinical Research and Development Center (FCRDC), Iran University of Medical Sciences (IUMS), Tehran, Iran.
PloS one
|November 19, 2024
概括
多发性硬化症患者表现出动脉内膜介质厚度 (CIMT) 的增加,这是动脉样硬化的一个标志物. 年龄和BMI是关键预测因素,表明MS和心血管风险之间存在联系.
科学领域:
- 神经学 神经学
- 心血管医学 心血管医学
- 血管生物学 血管生物学
背景情况:
- 多发性硬化症 (MS) 涉及中枢神经系统的炎症和脱髓化.
- 新出现的证据将多发性硬化与增加动脉样硬化风险和心血管并发症联系在一起.
- 了解这种关联对于管理多发性硬化患者的健康至关重要.
研究的目的:
- 为了调查影响多发性硬化症 (pwMS) 患者动脉样硬化发展的因素.
- 为了评估心动脉内心介质厚度 (CIMT) 作为pwMS中动脉样硬化的标志物.
- 为了确定MS人口中CIMT升高的预测因素.
主要方法:
- 一项涉及114名pwMS和127名对照者的比较研究.
- 动脉内膜厚度 (CIMT) 的测量和组间的比较.
- 在CIMT上分析包括年龄,BMI,EDSS,疾病持续时间和DMT在内的因素.
主要成果:
- 尽管调整了年龄,性别和BMI (p < 0.001),pMS的CIMT显著高于对照组.
- CIMT与年龄,BMI,EDSS得分和疾病持续时间 (p <0.05) 有显著的相关性.
- 二次进展性多发性硬化症 (SPMS) 病程与较高的CIMT相关 (p < 0.001);年龄和BMI是关键预测因素.
结论:
- 多发性硬化与增加的CIMT显著相关,表明动脉样硬化风险增加.
- 年龄是pwMS中CIMT升高的主要预测因素,其次是BMI.
- 结果表明MS和心血管风险之间存在联系,需要进一步研究机制和结果.
相关概念视频
01:30Atherosclerosis I: Introduction
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
01:27Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...